Current Enzyme Inhibition

Current Enzyme Inhibition

Editor-in-Chief

ISSN (Print): 1573-4080
ISSN (Online): 1875-6662

Research Article

Design of Novel Acat Inhibitors as Potent Anti-Hyperlipidemic Agents Using Chemometric Approaches

Author(s): Shagufta Khanorcid of author, Sarvesh Paliwalorcid of author, Smita Jainorcid of author and Pragya Sharma*

Volume 21, Issue 1, 2025

Published on: 02 December, 2024

Page: [61 - 74] Pages: 14

DOI: 10.2174/0115734080320466241003103148

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Aim: A 2D QSAR study of acyl-coenzyme A (CoA): cholesterol acyltransferase (ACAT) inhibitors revealed that electronic, topological, and steric properties are important structural features required for activity against ACAT.

Background: In order to interpret the evidence encrypted by the molecular structure of the compounds, a standard physicochemical descriptors-centered, and Quantitative Structure-Activity Relationship (QSAR) approach was implemented on a data set of Indoline derivatives were reported to be acyl-coenzyme A (CoA): cholesterol acyltransferase ACAT inhibitors.

Objective: The ACAT enzyme plays an important role in the absorption of dietary cholesterol. Therefore, the inhibition of ACAT is a key strategy or primary objective for the treatment of hypercholesterolemia and atherosclerosis.

Methods: Chemo metric models were designed by inserting a battery of statistical techniques in the current study that demonstrate the linear approaches of analysis, including multiple linear regression (MLR), partial least square PLS, and non-linear methods such as artificial neural networks (ANN).

Results: The activity contributions of these molecules were analyzed through regression equation, and the best QSAR model was created with an excellent correlative and predictive ability. Significant statistical values S = 0.35, F = 60.30, r = 0.92, r² = 0.85, r² (CV) = 0.82 of the designed models were obtained using stepwise MLR and a comparable PLS and FFNN model with r² (CV) = 0.82, 0.88 and 0.86 respectively and the relevant descriptors like inertia moment 1 size, Kier Chiv4 (cluster) index, Kier Chiv6(ring) index offered important information regarding this model.

Conclusion: The model reveals that inertia moment 1 size, Kier Chiv4 (cluster) index, and Kier Chiv6 (ring) index are prerequisite descriptors to determine other promising ACAT antagonists with high and liable potency against the target. Therefore, these characteristics may be used efficiently for the design and evaluation of active compounds as new ACAT inhibitors thanks to their utilization.

Keywords: QSAR, ACAT, FFNN, MLR, PLS, hypercholesterolemia.

Graphical Abstract

[1]
(a) Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis. A multifactorial disease. Circulation 1993; 87(3): II3-II16.
[PMID: 8443920];
(b) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-9.
[PMID: 7968073];
c) Shepherd J. The west of Scotland Coronary Prevention study: A trial of cholesterol reduction in scottish men. Am J Cardiol 1995; 76(9): 113C-7C.
[http://dx.doi.org/10.1016/S0002-9149(99)80480-9] [PMID: 7572679];
(d) Karam I, Yang YJ, Li JY. Hyperlipidemia Background and Progress. SM J Cardiolog and Cardiovasc Disord 2017; 3(2): 2-8.;
(e) Stoll F, Eidam A, Michael L, Bauer JM, Haefeli WE. Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents. Drugs Aging 2022; 39(4): 251-6.
[http://dx.doi.org/10.1007/s40266-022-00928-z] [PMID: 35278206];
(f) The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251(3): 365-74.
[http://dx.doi.org/10.1001/jama.1984.03340270043026] [PMID: 6361300]
[2]
Brown MS, Dana SE, Goldstein JL. Cholesterol ester formation in cultured human fibroblasts. Stimulation by oxygenated sterols. J Biol Chem 1975; 250(10): 4025-7.
[http://dx.doi.org/10.1016/S0021-9258(19)41498-1] [PMID: 1126942]
[3]
Bayly GR. Clinical Biochemistry: Metabolic and Clinical Aspects Clinical biochemistry: Metabolic and clinical aspects. Churchill Livingstone 2014; pp. 702-36.
[4]
a) Puglielli L, Konopka G, Pack-Chung E, et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide. Nat Cell Biol 2001; 3(10): 905-12.
[http://dx.doi.org/10.1038/ncb1001-905] [PMID: 11584272];
b) Chang TY, Chang CCY, Lin S, Yu C, Li BL, Miyazaki A. Roles of acyl-coenzyme A: cholesterol acyltransferase-1 and -2. Curr Opin Lipidol 2001; 12(3): 289-96.
[http://dx.doi.org/10.1097/00041433-200106000-00008] [PMID: 11353332]
[5]
(a) Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52(1): 223-61.
[http://dx.doi.org/10.1146/annurev.bi.52.070183.001255] [PMID: 6311077];
(b) Largis EE, Wang CH, DeVries VG, Schaffer SA. CL 277,082: A novel inhibitor of ACAT-catalyzed cholesterol esterification and cholesterol absorption. J Lipid Res 1989; 30(5): 681-90.
[http://dx.doi.org/10.1016/S0022-2275(20)38328-0] [PMID: 2760542];
(c) Carr TP, Parks JS, Rudel LL. Hepatic ACAT activity in African green monkeys is highly correlated to plasma LDL cholesteryl ester enrichment and coronary artery atherosclerosis. Arterioscler Thromb 1992; 12(11): 1274-83.
[http://dx.doi.org/10.1161/01.ATV.12.11.1274] [PMID: 1420087];
(d) Krause BR, Anderson M, Bisgaier CL, et al. In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J Lipid Res 1993; 34(2): 279-94.
[http://dx.doi.org/10.1016/S0022-2275(20)40755-2] [PMID: 8429262];
(e) Burrier RE, Deren S, McGregor DG, Hoos LM, Smith AA, Davis HR Jr. Demonstration of a direct effect on hepatic acyl CoA:cholesterol acyl transferase (ACAT) activity by an orally administered enzyme inhibitor in the hamster. Biochem Pharmacol 1994; 47(9): 1545-51.
[http://dx.doi.org/10.1016/0006-2952(94)90530-4] [PMID: 8185666]
[6]
Prasad K, Mishra M. Mechanism of hypercholesterolemia-induced atherosclerosis. Rev Cardiovasc Med 2022; 23(6): 212.
[http://dx.doi.org/10.31083/j.rcm2306212] [PMID: 39077184]
[7]
a) Gillies PJ, Robinson CS, Rathgeb KA. Regulation of ACAT activity by a cholesterol substrate pool during the progression and regression phases of atherosclerosis: Implications for drug discovery. Atherosclerosis 1990; 83(2-3): 177-85.
[http://dx.doi.org/10.1016/0021-9150(90)90163-D] [PMID: 2242095];
b) Sliskovic DR, White AD. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol Sci 1991; 12(5): 194-9.
[http://dx.doi.org/10.1016/0165-6147(91)90546-5] [PMID: 1862535]
[8]
Setia N, Verma IC, Khan B, Arora A. Premature coronary artery disease and familial hypercholesterolemia: Need for early diagnosis and cascade screening in the Indian population. Cardiol Res Pract 2012; 2012: 1-4.
[http://dx.doi.org/10.1155/2012/658526] [PMID: 22111029]
[9]
Kubinyi H. QSAR and 3D QSAR in drug design Part 1: Methodology. Drug Discov Today 1997; 2(11): 457-67.
[http://dx.doi.org/10.1016/S1359-6446(97)01079-9]
[10]
Patankar SJ, Jurs PC. Prediction of IC50 values for ACAT inhibitors from molecular structure. J Chem Inf Comput Sci 2000; 40(3): 706-23.
[http://dx.doi.org/10.1021/ci990125r] [PMID: 10850775]
[11]
Li X, Zou Y, Zhao Q, et al. Synthesis, biological evaluation, and molecular docking studies of xanthone sulfonamides as ACAT inhibitors. Chem Biol Drug Des 2015; 85(3): 394-403.
[http://dx.doi.org/10.1111/cbdd.12419] [PMID: 25146964]
[12]
Shoji Y, Takahashi K, Ohta M, et al. Novel indoline-based acyl-CoA: Cholesterol acyltransferase inhibitor: Effects of introducing a methanesulfonamide group on physicochemical properties and biological activities. Bioorg Med Chem 2009; 17(16): 6020-31.
[http://dx.doi.org/10.1016/j.bmc.2009.06.047] [PMID: 19608421]
[13]
Sharma P, Paliwal S, Sharma S, Chauhan N, Jain S. Quantitative structure activity relationship studies of potent Endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. Indian J Chem 2024; 63: 190-202.
[14]
Dalby A, Nourse JG, Hounshell WD, et al. Description of several chemical structure file formats used by computer programs developed at Molecular Design Limited. J Chem Inf Comput Sci 1992; 32(3): 244-55.
[http://dx.doi.org/10.1021/ci00007a012]
[15]
Sadowski J, Gasteiger J. From atoms and bonds to three-dimensional atomic coordinates: Automatic model builders. Chem Rev 1993; 93(7): 2567-81.
[http://dx.doi.org/10.1021/cr00023a012]
[16]
Kovatcheva A, Buchbauer G, Golbraikh A, Wolschann P. QSAR modeling of α-campholenic derivatives with sandalwood odor. J Chem Inf Comput Sci 2003; 43(1): 259-66.
[http://dx.doi.org/10.1021/ci020296n] [PMID: 12546561]
[17]
Kumar Pali S, Pandey A, Paliwal S. Quantitative Structure Activity Relationship Analysis of N-(mercaptoalkanoyl)- and [(acylthio)alkanoyl] Glycine Derivatives as ACE Inhibitors. Am J Drug Discov Develop 2011; 1(2): 85-104.
[http://dx.doi.org/10.3923/ajdd.2011.85.104]
[18]
Paliwal S, Narayan A, Paliwal S. Quantitative Structure Activity Relationship Analysis of Dicationic Diphenylisoxazole as Potent Anti‐Trypanosomal Agents. QSAR Comb Sci 2009; 28(11-12): 1367-75.
[http://dx.doi.org/10.1002/qsar.200860206]
[19]
Luco JM, Ferretti FH. QSAR based on multiple linear regression and PLS methods for the anti-HIV activity of a large group of HEPT derivatives. J Chem Inf Comput Sci 1997; 37(2): 392-401.
[http://dx.doi.org/10.1021/ci960487o] [PMID: 9090857]
[20]
Mittal A, Sharma M, Singh A. QSAR Modelling of PDE5 Inhibitory Activity of Tetracyclic Guanine Derivatives as Antihypertensive Agents. Int J Drug Dev Res 2016; 8(3): 043-51.
[21]
Kesar S, Paliwal S, Sharma S, et al. In-Silico QSAR Modelling of Predicted Rho Kinase Inhibitors Against Cardio Vascular Diseases. Curr Computeraided Drug Des 2019; 15(5): 421-32.
[http://dx.doi.org/10.2174/1573409915666190307163437] [PMID: 30848208]
[22]
Rinaldi D, Rivail JL. Molecular polarizability and dielectric effect of medium in the liquid phase. Theoretical study of the water molecule and its dimers. Theor Chim Acta 1973; 32(1): 57-70.
[http://dx.doi.org/10.1007/BF01209416]
[23]
Khan S, Najmi AY, Kesar S, Madan K, Arya R. Development of QSAR Model using MLR, PLS and NN Approach to Elucidate the Physicochemical Properties Responsible for Antihyperlipidemic Potential of ACAT inhibitors. YMER 2023; 22(3): 981-99.
[24]
Jain S, Chauhan N, Bhardwaj A, Yadaw G, Singh MK, Mishra A. QSAR Modeling of α-Ketooxazole Motif Analogues as Potent Anti-Alzheimer Agents. YMER Digital 2022; 21(5): 624-40.
[http://dx.doi.org/10.37896/YMER21.05/71]
[25]
Kursula P, Sikkilä H, Fukao T, Kondo N, Wierenga RK. High resolution crystal structures of human cytosolic thiolase (CT): A comparison of the active sites of human CT, bacterial thiolase, and bacterial KAS I. J Mol Biol 2005; 347(1): 189-201.
[http://dx.doi.org/10.1016/j.jmb.2005.01.018] [PMID: 15733928]

Rights & Permissions Print Cite